logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Fate Therapeutics, Inc.


USPTO Granted Patents = 51

% Expired Patents = 5.9



Trademarks = 6

Forward Citations = 193

Loading Chart...
Loading Chart...

36 inventors (with patents filed for the assignee):

goldMedal Bahram Valamehr (36 out of 36 patents)

silverMedal Ryan Bjordahl (19 out of 19 patents)

bronzeMedal Tom Tong Lee (13 out of 13 patents)

4.  Raedun Clarke (12 out of 12 patents)

5.  Ramzey Abujarour (11 out of 11 patents)

6.  Peter Flynn (10 out of 10 patents)

7.  Betsy Rezner (8 out of 8 patents)

8.  David Robbins (7 out of 13 patents)

9.  Eigen Peralta (7 out of 7 patents)

10.  Jonathan Rosen (6 out of 6 patents)

11.  John D Mendlein (5 out of 87 patents)

12.  Jode Goodridge (5 out of 5 patents)

13.  Megan Robinson (5 out of 5 patents)

14.  Daniel D Shoemaker (5 out of 26 patents)

15.  Ian Hardy (4 out of 5 patents)


Core Competencies:
Genomic Engineering
Pluripotent Cells
iPSC Derived Cells
Immunotherapies
Hematopoietic Differentiation
Cell Culture Platforms
Tumor Targeting
Chimeric Antigen Receptor
Cell Potency Assay
Stem Cell Media
Small Molecule Compounds
Single Cell Sorting

51 patents:

1. 12642852 - Genomic engineering of pluripotent cells (2026-06-02),
2. 12618049 - REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS (2026-05-05),
3. D1118968 - Vial rack (2026-03-17),
4. 12435123 - Immunotherapies using enhanced iPSC derived effector cells (2025-10-07),
5. 12419870 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2025-09-23),
6. 12415989 - Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs (2025-09-16),
7. 12410403 - Methods and compositions for inducing hematopoietic cell differentiation (2025-09-09),
8. 12398373 - Enhanced immune effector cells and use thereof (2025-08-26),
9. 12385012 - Methods and compositions for inducing hematopoietic cell differentiation (2025-08-12),
10. 12351831 - Platform for the induction and maintenance of ground state pluripotency (2025-07-08),
11. 12281329 - Compositions and methods for immune cell modulation in adoptive immunotherapies (2025-04-21),
12. 12275955 - Combining iPSC derived effector cell types for immunotherapy use (2025-04-14),
13. 12264322 - Minimal volume reprogramming of mononuclear cells (2025-04-01),
14. 12247226 - Cellular reprogramming using temporal and transient plasmid vector expression system (2025-03-11),
15. 12203098 - Cells having solid tumor targeting backbone and use thereof (2025-01-21),
Fate Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in cellular engineering. The company focuses on developing innovative cell-based immunotherapies, leveraging its expertise in genomic engineering and induced pluripotent stem cell (iPSC) technology. Fate Therapeutics aims to create advanced therapeutic solutions through hematopoietic differentiation and tumor targeting, utilizing cutting-edge cell culture platforms to enhance the efficacy of its treatments in oncology and other diseases.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

51 Patents

#119 in San Diego, CA

#1,618 in California

#6,876 in US

#13,753 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Fate Therapeutics, Inc.

Forward Citations = 193

36 inventors:

goldMedal Bahram Valamehr (36 out of 36 patents)

silverMedal Ryan Bjordahl (19 out of 19 patents)

bronzeMedal Tom Tong Lee (13 out of 13 patents)

4.  Raedun Clarke (12 out of 12 patents)

5.  Ramzey Abujarour (11 out of 11 patents)

Please report any incorrect information to [email protected]
Loading…